Advancing structured decision-making in drug regulation at the FDA and EMA.

British Journal of Clinical Pharmacology
Aris Angelis, Lawrence D Phillips

Abstract

The recent benefit-risk framework (BRF) developed by the Food and Drug Administration (FDA) is intended to improve the clarity and consistency in communicating the reasoning behind the FDA's decisions, acting as an important advancement in US drug regulation. In the PDUFA VI implementation plan, the FDA states that it will continue to explore more structured or quantitative decision analysis approaches; however, it restricts their use within the current BRF that is purely qualitative. By contrast, European regulators and researchers have been long exploring the use of quantitative decision analysis approaches for evaluating drug benefit-risk balance. In this paper, we show how quantitative modelling, backed by decision theory, could complement and extend the FDA's BRF to better support the appraisal of evidence and improve decision outcomes. After providing relevant scientific definitions for benefit-risk assessment and describing the FDA and European Medicines Agency (EMA) frameworks, we explain the components of and differences between qualitative and quantitative approaches. We present lessons learned from the EMA experience with the use of quantitative modelling and we provide evidence of its benefits, illustrated by a real...Continue Reading

References

Jan 1, 1983·Medical Decision Making : an International Journal of the Society for Medical Decision Making·R W Chang, H V Fineberg
Aug 1, 1965·Journal of Personality and Social Psychology·J S BRUNER, H TAJFEL
Apr 3, 2009·The New England Journal of Medicine·Hans-Georg EichlerTomas Salmonson
Jul 31, 2010·Nature Reviews. Drug Discovery·Michael Hay
Jun 29, 2011·The New England Journal of Medicine·Daniel CarpenterSteven Joffe
Feb 14, 2013·European Journal of Public Health·Lawrence D PhillipsThomas Lönngren
Mar 27, 2013·JAMA Internal Medicine·Staffan SvenssonJoel Lexchin
Apr 1, 2011·Drug Discovery Today. Technologies
Jun 17, 2014·Pharmaceutical Statistics·Jonathan Haddad
Jan 18, 2015·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Andrea R BeyerH L Hillege
Apr 16, 2015·Risk Analysis : an Official Publication of the Society for Risk Analysis·Gilberto Montibeller, Detlof von Winterfeldt
Jan 23, 2016·Pharmacoepidemiology and Drug Safety·Diana HughesUNKNOWN PROTECT Benefit-Risk Group
Oct 1, 2013·Journal of Vascular Surgery. Venous and Lymphatic Disorders·Jose Pablo MoralesKenneth J Cavanaugh
Mar 30, 2016·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Kevin MarshUNKNOWN ISPOR Task Force
Oct 25, 2016·JAMA : the Journal of the American Medical Association·Aaron S Kesselheim, Jerry Avorn
Jan 24, 2017·JAMA : the Journal of the American Medical Association·Robert M Califf
Jul 14, 2017·The Journal of Pharmacy and Pharmacology·Andrew MooreK D Rainsford
May 2, 2018·Therapeutic Innovation & Regulatory Science·Nancy A Dreyer
Feb 4, 2019·Drug Discovery Today·Jonathan J Darrow
May 14, 2019·Clinical Pharmacology and Therapeutics·Rajanikanth MadabushiIssam Zineh

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.